The market is witnessing significant growth, driven by advancements in molecular biology techniques and increasing applications in research, clinical diagnostics, and forensics. Digital PCR offers higher sensitivity, precision, and reproducibility compared to traditional PCR methods, making it increasingly valuable in various fields.
One of the key drivers of the market is the rising demand for accurate and reliable molecular diagnostic tools. Digital PCR enables the detection and quantification of nucleic acids with unparalleled precision, making it ideal for applications such as cancer biomarker detection, infectious disease diagnosis, and genetic testing.
The growing prevalence of chronic diseases and the need for early and accurate diagnosis are further fueling the adoption of digital PCR technology. Another factor driving market growth is the increasing focus on personalized medicine and precision healthcare. Digital PCR allows for the detection of genetic variations and mutations associated with diseases, enabling clinicians to tailor treatments based on individual genetic profiles. This has led to a growing demand for digital PCR technologies in pharmacogenomics and companion diagnostics.
The Global Digital Polymerase Chain Reaction (PCR) Market size was valued at USD 6.83 billion in 2023 and is projected to reach USD 15.86 billion by 2031, with a CAGR of 11.1% during the forecast period of 2024 to 2031.
Below are the Top Five Digital Polymerase Chain Reaction (PCR) Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann- La Roche Ltd
|
F. Hoffmann-La Roche AG, commonly known as Roche, is a leading multinational healthcare company headquartered in Basel, Switzerland. The company operates in the pharmaceuticals and diagnostics sectors, with a strong presence in the digital polymerase chain reaction (PCR) market. Roche's involvement in the digital PCR market is through its subsidiary, Roche Molecular Systems. Roche offers a range of digital PCR solutions under the cobas brand, including the cobas z 480 analyzer. The cobas z 480 analyzer is a fully automated digital PCR system that enables precise and reliable quantification of nucleic acids for various applications, including infectious disease testing, oncology, and research. Roche is known for its strong focus on innovation and research, consistently investing in the development of advanced technologies and products. The company's commitment to precision medicine has led to the development of tailored therapies and diagnostic solutions, including those utilizing digital PCR technology.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In August 2022, F. Hoffmann-La Roche Ltd launched a digital PCR system named Digital Light Cycler system. The company stated that it is designed to accurately quantify trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods. It will also help the company in PCR portfolio expansion.
|
|
2.
|
BIO-RAD LABORATORIES, INC
|
Bio-Rad Laboratories, Inc. is a global leader in life science research and clinical diagnostics, with a strong presence in the digital polymerase chain reaction (PCR) market. The company is headquartered in Hercules, California, and operates in more than 100 countries worldwide. Bio-Rad offers a range of digital PCR solutions under its Droplet DigitalPCR (ddPCR) technology platform. ddPCR is a highly precise and sensitive method for nucleic acid detection and quantification, enabling researchers and clinicians to achieve accurate results in various applications, including cancer research, infectious disease detection, and genetic testing.
Bio-Rad's ddPCR systems, such as the QX200 Droplet Digital PCR System, offer high-throughput capabilities and superior performance compared to traditional PCR methods. These systems enable researchers to detect and quantify nucleic acids with unparalleled precision, making them valuable tools in molecular diagnostics and research.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In April 2024, Bio-Rad Laboratories, Inc. announced a collaboration with Oncocyte Corporation, a precision diagnostics company. The collaboration aims to develop and market transplant monitoring products utilizing Bio-Rad’s Droplet Digital PCR (ddPCR) instruments and reagents. As part of the agreement, Bio-Rad will invest in a private placement of Oncocyte’s equity and gain exclusive commercialization rights in specific markets for Oncocyte’s assay designed for transplant monitoring research, utilizing Bio-Rad’s QX600 ddPCR System.
|
|
3.
|
Merck KGaA
|
Merck KGaA, commonly known as Merck, is a leading multinational pharmaceutical, chemical, and life sciences company headquartered in Darmstadt, Germany. The company has a strong presence in the digital polymerase chain reaction (PCR) market through its Life Science business sector. Merck offers a range of products and solutions for molecular biology and PCR applications, including digital PCR. The company's digital PCR solutions are designed to provide researchers and clinicians with accurate and reliable tools for nucleic acid quantification and analysis. Merck's digital PCR systems offer high sensitivity, precision, and reproducibility, making them ideal for a wide range of applications, such as gene expression analysis, mutation detection, and pathogen detection.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In January 2021, Merck KGaA announced the acquisition of AmpTec, a leading Hamburg, Germany-based mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applications.
|
|
4.
|
THERMO FISHER SCIENTIFIC
|
Thermo Fisher Scientific Inc. is a global leader in serving science, with a strong presence in the digital polymerase chain reaction (PCR) market. The company is headquartered in Waltham, Massachusetts, and operates in more than 180 countries worldwide.
Thermo Fisher offers a wide range of digital PCR solutions under its Applied Biosystems brand. The company's digital PCR systems, such as the QuantStudio 3D Digital PCR System, are designed to provide researchers and clinicians with accurate and reliable tools for nucleic acid quantification and analysis. Thermo Fisher's digital PCR technology offers high sensitivity, precision, and reproducibility, making it well-suited for a variety of applications, including oncology research, infectious disease detection, and genetic testing.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In December 2022, Thermo Fisher Scientific, the world leader in serving science, announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases. TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens. This will help the organization in developing overall revenue.
|
|
5.
|
qiagen
|
QIAGEN is a leading global provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company is headquartered in Venlo, Netherlands, and has offices in more than 35 countries, serving customers in over 130 countries.
QIAGEN offers a range of digital polymerase chain reaction (PCR) solutions under its QIAcuity™ Digital PCR System. The QIAcuity Digital PCR System provides researchers and clinicians with a highly sensitive and precise tool for nucleic acid quantification and analysis. The system offers high throughput and scalability, making it suitable for a wide range of applications, including cancer research, infectious disease detection, and genetic testing.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In July 2023, QIAGEN expanded the range of digital PCR kits and services for the biopharma industry by partnering with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers. The company said the partnership between QIAGEN and Niba Labs will bring an analytical laboratory with extensive expertise in digital PCR assay development and sample testing, which will allow QIAcuity customers to use the combined expertise of both companies to develop new custom simplex or multiplex assays for the quantification of nucleic acid.
|
Conclusion
The market is experiencing significant growth and innovation, driven by advancements in technology and increasing demand for precision diagnostics. Companies such as Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories are leading the way with their cutting-edge digital PCR solutions, which offer high sensitivity, accuracy, and scalability for various applications in molecular diagnostics, research, and beyond. Key drivers such as the rising prevalence of chronic diseases, increasing adoption of personalized medicine, and growing investments in life sciences research are fueling market expansion. In addition, factors such as the integration of digital PCR technology into automotive systems, smart home devices, and virtual assistants are opening up new opportunities for market growth. Overall, the future looks promising for the market, with continued technological advancements and a growing focus on personalized medicine driving the market forward.
